Midregional Proadrenomedullin Predicts Mortality and Major Adverse Cardiac Events in Patients Presenting With Chest Pain: Results From the CHOPIN Trial (original) (raw)

Profile image of Inder Anand Inder Anand Profile image of Gary Vilke Gary Vilke Profile image of Lori Daniels Lori Daniels

2015, Academic Emergency Medicine

visibility

…

description

10 pages

link

1 file

Objectives: Chest pain is a common complaint to emergency departments (EDs) and clinical risk factors are used to predict which patients are at risk for worse outcomes and mortality. The goal was to assess the novel biomarker midregional proadrenomedullin (MR-proADM) in prediction of mortality and major adverse cardiac events (MACE).